2MN

Metronidazole

Find entries where: 2MN

is present as a standalone ligand in 1 entries

Find related ligands:

Chemical Component Summary
Name	Metronidazole
Identifiers	2-(2-methyl-5-nitro-imidazol-1-yl)ethanol
Formula	C₆ H₉ N₃ O₃
Molecular Weight	171.154
Type	NON-POLYMER
Isomeric SMILES	Cc1ncc(n1CCO)[N+](=O)[O-]
InChI	InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3
InChIKey	VAOCPAMSLUNLGC-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	21
Chiral Atom Count	0
Bond Count	21
Aromatic Bond Count	5

Drug Info: DrugBank

DrugBank ID	DB00916
Name	Metronidazole
Groups	approved
Description	Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics.[L3754] It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades[L7429], with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.
Synonyms	1-(β-oxyethyl)-2-methyl-5-nitroimidazole Metronidazole hydrochloride Metronidazol Metronidazolum 2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole Métronidazole 1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole Metronidazole 2-methyl-5-nitroimidazole-1-ethanol 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole 1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole 2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
Brand Names	Flagyl Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride Rosasol Vandazole Metronidazole 1% / Mupirocin 2% / Flagyl ER Nuvessa Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride HELIDAC Therapy Metronidazole Vaginal Gel, 0.75% Ivermectin 1% / Metronidazole 1% Bismuth Subsalicylate/Metronidazole/Tetracycline Hydrochloride Auro-metronidazole Flagyl 500 500mg MetroGel Florazole ER Metronidazole 1% / Mupirocin 2% Metronidazole 1% / Niacinamide 4% Metrogel Metronidazole 250 mg Novo-nidazol Tab 250mg Nidagel Mar-metronidazole MetroGel-Vaginal Metronidazole500 mg 500 mg Metrogel-Vaginal Noritate Metrocream - Crm 0.75% Metrogel 0.75% Ivermectin 1% / Metronidazole 1% / Niacinamide 4% Metronidazole Tab 250mg Metronidazole250 mg 250 mg MetroCream Truemed Group LLC PMS-metronidazole Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride PMS-metronidazole 250mg/tab Pylera Likmez MetroLotion M-metronidazole Metronidazole Injection, USP Metronidazole 500 mg Rosadan Vitazol Metronidazole Apo-metronidazole Brimonidine Tartrate 0.25% / Ivermectin 1% / Metronidazole 1% / Niacinamide 4% Metronidazole Vaginal Flagystatin Metronidazole Topical Cream, 0.75% Metronidazole Topical Gel Metronidazole Injection USP Rosaclear System Metronidazole Topical Cream Metrogel 1% 171083 Ivermectin 1% / Metronidazole 1% / Niacinamide 4% Mint-metronidazole
Indication	Metronidazole is indicated for the treatment of confirmed trichomoniasis caused by Trichomonas vaginalis (except for in the first trimester of pregnancy) and the patient's sexual partners, bacterial vaginosis,[L7432, L49811] certain types of amebiasis, and various anaerobic infections.[A181057, L49811] The above anaerobic infections may occur on the skin and skin structures, the abdomen, the heart, reproductive organs, central nervous system, and the respiratory system. Some may also be present in the bloodstream in cases of septicemia. Common infections treated by metronidazole are Bacteroides species infections, Clostridium infections, and Fusobacterium infections, as well as Peptococcus and Peptostreptococcus infections.[L3754] Topical formulations of metronidazole are indicated for the treatment of inflammatory lesions of rosacea.[L45166] It is also used off-label in the treatment of Crohn's disease, as a prophylactic agent after surgery[A181039], and in the treatment of Helicobacter pylori infection.[A181045] It has also been studied in the prevention of preterm births and to treat periodontal disease.[A1391,A181078]
Categories	Agents that reduce seizure threshold Alimentary Tract and Metabolism Anti-Bacterial Agents Anti-Infective Agents Antibacterials for Systemic Use Antiinfectives and Antiseptics for Local Oral Treatment Antiinfectives for Systemic Use Antiparasitic Agents Antiparasitic Products, Insecticides and Repellents Antiprotozoals Cytochrome P-450 CYP2A6 Substrates Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Inhibitors Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 CYP3A7 Substrates Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Dermatologicals Drugs for Acid Related Disorders Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) Genito Urinary System and Sex Hormones Gynecological Antiinfectives and Antiseptics Imidazole Derivatives Imidazoles Miscellaneous Antiprotozoals Miscellaneous Local Anti-infectives Nitro Compounds Nitroimidazole Antimicrobial Nitroimidazole Derivatives Nitroimidazoles P-glycoprotein inhibitors Potential QTc-Prolonging Agents QTc Prolonging Agents Stomatological Preparations UGT1A1 Substrates
ATC-Code	A02BD11 P01AB52 D06BX01 A02BD03 J01XD01 J01RA04 A02BD01 J01RA14 A02BD15 J01RA03 A01AB17 G01AF20 J01RA10 A02BD02 A02BD13 G01AF01 P01AB51 A02BD08 P01AB01
CAS number	443-48-1

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Oxygen-insensitive NADPH nitroreductase	MKFLDQEKRRQLLNERHSCKMFDSHYEFSSTELEEIAEIARLSPSSYNTQ...	unknown	potentiator
Anaerobic bacterial DNA	-	unknown	inhibitor
Protozoal DNA	-	unknown	inhibitor
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	inhibitor
UDP-glucuronosyltransferase 1-1	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...	unknown	substrate
Cytochrome P450 2A6	MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLN...	unknown	substrate
Cytochrome P450 3A5	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...	unknown	substrate
Cytochrome P450 3A7	MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNA...	unknown	substrate
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	inhibitor
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	inhibitor
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682